Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

MLA

Giannelli, Gianluigi, et al. “Correction: Biomarkers and Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with TGF-ΒRI Inhibitor Galunisertib.” PloS One, vol. 16, no. 6, June 2021, p. e0253671. EBSCOhost, https://doi.org/10.1371/journal.pone.0253671.

APA

Giannelli, G., Santoro, A., Kelley, R. K., Gane, E., Paradis, V., Cleverly, A., Smith, C., Estrem, S. T., Man, M., Wang, S., Lahn, M. M., Raymond, E., Benhadji, K. A., & Faivre, S. (2021). Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PloS One, 16(6), e0253671. https://doi.org/10.1371/journal.pone.0253671

Chicago

Giannelli, Gianluigi, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, et al. 2021. “Correction: Biomarkers and Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with TGF-ΒRI Inhibitor Galunisertib.” PloS One 16 (6): e0253671. doi:10.1371/journal.pone.0253671.